FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 402 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow April 12, 2023 Blinatumomab Improves Survival in Children with Relapsed Leukemia April 1, 2021 Mohs Surgery for Skin Cancer: What to Know and What to... March 28, 2023 ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer... September 18, 2026 Load more HOT NEWS Fears breast cancer progress could stall due to COVID-19 backlog Cancer in children and young people: how far we’ve come Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... Veteran and His Loyal Dog Pass Away Within Hours Of Each...
